Failure to obtain consent and provide psychotropic medication education: A resident with late onset Alzheimer’s Disease was started on multiple psychotropic meds, including an antidepressant, antipsychotic, antianxiety med, and another antidepressant, but the EHR did not show consent before initial administration. There were also no progress notes or assessments documenting education on side effects, risks vs benefits, or offering alternative treatments before the meds were given, despite facility policy requiring informed consent and discussion of nonpharmacological approaches and medication alternatives.
Failure to Document Consent and Education for Psychotropic Medications: The facility did not document consent, resident education, or discussion of alternative treatments before giving psychotropic medications to four residents with diagnoses including dementia, anxiety, depression, PTSD, insomnia, and bipolar disorder. Records showed orders for antidepressants, antianxiety medications, antipsychotics, and hypnotic agents, but no progress notes or assessments reflected education on risks and benefits or that alternatives were offered, and the facility had no policy for psychotropic medication use.
Failure to inform a resident representative of the risks and benefits and treatment alternatives before starting sertraline for a resident with dementia, depression, and severely impaired cognition. The EHR lacked documentation of advance notification or consent, the MAR showed daily administration of the SSRI, and both the Administrator and family representative confirmed no prior family consent or notification occurred.
Failure to obtain informed consent for psychotropic medications: A resident with severe cognitive impairment, dementia, insomnia, and other diagnoses received two antidepressants and one antipsychotic, but the record lacked documentation of family consent and/or education about adverse side effects and the risks and benefits of the medications. The DON stated the psychotropic consents were not completed with the family until later, and the Administrator said staff had not yet been trained on the process; the facility policy did not address when or how to obtain informed consent.
A resident with intact cognition on MDS, hearing impairment, and multiple chronic conditions was started on mirtazapine for depression without documented education or informed consent from the resident or a legal representative. After the antidepressant was initiated, staff documented marked drowsiness, confusion, and sleep talking, and the provider later reduced the dose. Interviews with the DON and MDS Coordinator confirmed the facility could not find consent documentation for the psychotropic medication.
Failure to Document Consent for Psychotropic Medication Changes: A resident with moderate cognitive impairment, Alzheimer’s disease, CVA, seizure disorder, anxiety, psychotic disorder, and a brain tumor received psychotropic meds including Buspirone, Quetiapine, and Citalopram. The record had consent for some initial orders, but lacked documentation of consent for a Buspirone dose increase, a Quetiapine restart, and the start and increase of Citalopram; the DON confirmed the missing documentation.
Failure to obtain informed consent for PRN psychotropic medications: A resident with unspecified dementia with psychotic disturbance had orders for IM ziprasidone and ABHR gel for agitation, aggression, and anxiety, but the chart lacked documentation of family consent and education on risks, benefits, and adverse effects. The DON confirmed psychotropic consents were not completed in the EHR, and the facility policy required informed consent before starting or increasing psychotropic meds.
The facility failed to fully inform two residents and/or their representatives about the risks and benefits of psychotropic medications before starting or changing the drugs. One resident with intact cognition had orders for clonazepam, trazodone, Lamictal, and buspirone, but the record lacked documentation of informed discussion, and the POA said staff did not explain what the meds were for or their risks and benefits. Another resident with intact cognition had aripiprazole, buspirone, and escitalopram ordered after admission, but the chart lacked a current psychotropic consent form; the DON acknowledged the only consent on file was from a prior admission.
Failure to obtain informed consent for psychotropic medication increases for two residents with intact cognition. One resident had sertraline increased and another had venlafaxine increased, but the EHR lacked documentation of consent from the resident or representative. A nurse consultant stated the consents were not available when the medications were increased, despite the facility policy requiring the resident or legal representative to be fully informed and able to participate in or refuse treatment.
A facility failed to obtain informed consent for psychotropic meds with black box warnings for 5 of 5 residents reviewed. Residents included individuals with intact cognition and others with severe cognitive impairment, with active orders for antidepressants, antipsychotics, and antianxiety meds such as sertraline, mirtazapine, clonazepam, Lexapro, clozapine, lorazepam, trazodone, Paxil, risperidone, and bupropion. The EHR lacked psychotropic consent documentation, and the DON stated she did not have informed consents.
Self-audit
Pick a level of detail and, optionally, what to focus on — then generate a survey-ready checklist distilled from the most recent citations.
Beta · AI-generated — for reference only, not professional advice. Verify against current CMS guidance before relying on it. Assisto accepts no responsibility for how this checklist is used.
Citations used to create this checklist
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release June 24, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.